Article

Lawmakers Hear Evidence of Gray Market in Shortage Drugs

An investigation by congressional staff concluded that so-called gray market companies were identifying weak points in the drug distribution system and taking steps to drive up prices for drugs that were determined to be in short supply.

These companies are profiteers that zero in on short-supply drugs and sell them at inflated prices, said Sen. Jay Rockefeller (D, W.Va.), chair of the Senate Committee on Commerce, Science and Transportation. During a July 25 committee hearing, Rockefeller unveiled the findings of a price-gouging investigation in which his office collaborated with the staffs of Sen. Tom Harkin (D, Iowa) and Rep. Elijah Cummings (D, Md.).

Read the full story: http://tinyurl.com/9tzy3mn

Source: amednews.com

Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Leigh Maria Ramos-Platt, MD
Molly Dean, MSW, Siftwell
Molly Dean, MSW, Siftwell
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Dr Andrew S. Oseran
o Richard Hughes IV, JD, MPH, Epstein Becker Green
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo